Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al
- PMID: 32520641
- PMCID: PMC7374615
- DOI: 10.1089/scd.2020.0089
Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al
Conflict of interest statement
S.K.L. is founder of Paracrine Therapeutics and has scientific advisory role at Ilias Biologics and ExoCo. B.G. is scientific advisory board member of Evox Therapeutics and Innovex Therapeutics SL. The others authors have nothing to disclose.
Comment on
-
Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.Stem Cells Dev. 2020 Jun 15;29(12):747-754. doi: 10.1089/scd.2020.0080. Epub 2020 May 12. Stem Cells Dev. 2020. PMID: 32380908 Free PMC article. Clinical Trial.
References
-
- Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andrianstsitohaina R, Antoniou A, Arab T, Archer et al F (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7:1535750. - PMC - PubMed
-
- Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussolatti B, Carter DRF, Dominici M, Falcón-Pérez JM, Gimona M, et al. (2020). ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19. Cytotherapy [Epub ahead of print]; DOI: 10.1016/j.jcyt.2020.05.002 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
